Malnutrition and Insulin Resistance May Interact with Metabolic Syndrome in Prevalent Hemodialysis Patients

Background: We sought to determine the prevalence of metabolic syndrome (Mets) and whether 100 cm2 of visceral fatty area (VFA) measured by computed tomography (CT) validates the criteria of waist circumference (WC) in hemodialysis (HD) patients. Methods: The study comprised 141 HD patients. Mets was defined according to the criteria of Adult Treatment Panel III (ATP III) and the modified criteria of National Cholesterol Education Program (NCEP) that defines abdominal obesity as a WC of >=85 cm in men and >=90 cm in women. Results: The prevalence of Mets was 31.9% in men and 13.6% in women. However, the prevalence of patients with a body mass index over 25 in all HD patients was only 11.2%. The visceral fatty area (VFA) measured by CT showed a strong positive correlation with WC. The patients with Mets, comparing with those without Mets, have significantly shorter duration of HD, higher high-sensitive C-reactive protein, and higher Homeostatic Model Assessment for Insulin Resistance (HOMA-IR). In the patients with Mets, there was a significant negative correlation between HOMA-IR and serum albumin levels. Multivariate logistic regression analysis showed that HOMA-IR and short duration of HD were chosen as independent risk factors for Mets. Conclusions: Mets is more prevalent in HD patients. In Japanese HD patients, 100 cm2 of VFA corresponded to a WC of 85 cm in men and 90 cm in women, thus confirming the validity of the modified criteria. HOMA-IR and serum albumin were significantly correlated in HD patients with Mets.

[1]  Y. Dimitrov,et al.  Metabolic syndrome in haemodialysis patients: prevalence, determinants and association to cardiovascular outcomes , 2020, BMC Nephrology.

[2]  K. Alswat,et al.  Prevalence of Metabolic Syndrome Among the End-Stage Renal Disease Patients on Hemodialysis , 2017, Journal of clinical medicine research.

[3]  A. Ichihara,et al.  Visceral Fat Level Is an Independent Risk Factor for Cardiovascular Mortality in Hemodialysis Patients , 2014, American Journal of Nephrology.

[4]  Daniel O. Young,et al.  Prevalence of the metabolic syndrome in an incident dialysis population , 2007, Hemodialysis international. International Symposium on Home Hemodialysis.

[5]  A. Gotto,et al.  The metabolic syndrome: a call to action. , 2006, Coronary artery disease.

[6]  K. Iseki,et al.  Metabolic syndrome and chronic kidney disease in Okinawa, Japan. , 2006, Kidney international.

[7]  Richard Kahn,et al.  The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. , 2005, Diabetes care.

[8]  T. Ohtake,et al.  Insulin resistance in patients with chronic kidney disease. , 2005, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[9]  K. Johansen,et al.  Association of body size with outcomes among patients beginning dialysis. , 2004, The American journal of clinical nutrition.

[10]  K. Iseki,et al.  Body mass index and the risk of development of end-stage renal disease in a screened cohort. , 2004, Kidney international.

[11]  Jing Chen,et al.  The Metabolic Syndrome and Chronic Kidney Disease in U.S. Adults , 2004, Annals of Internal Medicine.

[12]  R. Turner,et al.  Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man , 1985, Diabetologia.

[13]  ChristianRask-Madsen,et al.  Tumor Necrosis Factor-α Inhibits Insulin’s Stimulating Effect on Glucose Uptake and Endothelium-Dependent Vasodilation in Humans , 2003 .

[14]  L. Køber,et al.  Tumor Necrosis Factor-&agr; Inhibits Insulin’s Stimulating Effect on Glucose Uptake and Endothelium-Dependent Vasodilation in Humans , 2003, Circulation.

[15]  P. Whelton,et al.  Insulin resistance and risk of chronic kidney disease in nondiabetic US adults. , 2003, Journal of the American Society of Nephrology : JASN.

[16]  Jukka T Salonen,et al.  The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. , 2002, JAMA.

[17]  H. Koyama,et al.  Insulin resistance as an independent predictor of cardiovascular mortality in patients with end-stage renal disease. , 2002, Journal of the American Society of Nephrology : JASN.

[18]  B. Egan,et al.  Insulin resistance and cardiovascular disease. , 2001, American journal of hypertension.

[19]  L. Groop,et al.  Cardiovascular morbidity and mortality associated with the metabolic syndrome. , 2001, Diabetes care.

[20]  J. Mckenney,et al.  Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). , 2001, JAMA.

[21]  M. Nagase,et al.  Impact of dialysis therapy on insulin resistance in end-stage renal disease: comparison of haemodialysis and continuous ambulatory peritoneal dialysis. , 2000, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[22]  P. Stenvinkel,et al.  Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. , 1999, Kidney international.

[23]  J. Després,et al.  The Dense LDL Phenotype: Association with plasma lipoprotein levels, visceral obesity, and hyperinsulinemia in men , 1996, Diabetes Care.

[24]  A. Baron,et al.  Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance. , 1996, The Journal of clinical investigation.

[25]  S. Haffner,et al.  Prospective Analysis of The Insulin-Resistance Syndrome (Syndrome X) , 1992, Diabetes.

[26]  Y. Matsuzawa,et al.  A novel technique for the determination of body fat by computed tomography. , 1983, International journal of obesity.